

Benjamin Hibbert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7615221/publications.pdf>

Version: 2024-02-01

114
papers

2,512
citations

201674

27
h-index

243625

44
g-index

116
all docs

116
docs citations

116
times ranked

4053
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison. Platelets, 2022, 33, 298-303.	2.3	3
2	Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease. Coronary Artery Disease, 2022, 33, 98-104.	0.7	1
3	“Primary” percutaneous mitral valve repair in patients with acute myocardial infarction: is it ready for primetime?. European Heart Journal, 2022, 43, 651-653.	2.2	3
4	Association of annual volume and in-hospital outcomes of catheter-directed thrombolysis for pulmonary embolism. Catheterization and Cardiovascular Interventions, 2022, 99, 440-446.	1.7	6
5	Inotropes for cardiogenic shock “ Six of one, half a dozen of the other. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101004.	1.4	2
6	Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial. Journal of the American Heart Association, 2022, 11, e023322.	3.7	15
7	Utility of a smartphone application in assessing palmar circulation prior to radial artery harvesting for coronary artery bypass grafting: rationale and design of the randomised CAPITAL iRADIAL-CABG trial. BMJ Open, 2022, 12, e055580.	1.9	0
8	Significant valvular dysfunction and outcomes in cardiogenic shock: insights from the randomized DOREMI trial. Canadian Journal of Cardiology, 2022, , .	1.7	10
9	Device-related thrombus following left atrial appendage occlusion. EuroIntervention, 2022, 18, 224-232.	3.2	15
10	No sex-based difference in cardiogenic shock: A post-hoc analysis of the DOREMI trial. Journal of Cardiology, 2022, , .	1.9	2
11	Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation. JACC: Cardiovascular Interventions, 2021, 14, 1-11.	2.9	59
12	The secretome of liver X receptor agonist-treated early outgrowth cells decreases atherosclerosis in <i>Ldlr^{-/-}</i> mice. Stem Cells Translational Medicine, 2021, 10, 479-491.	3.3	5
13	Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk. Clinical and Translational Science, 2021, 14, 354-361.	3.1	8
14	Sex-specific in-hospital outcomes of transcatheter aortic valve replacement with third generation transcatheter heart valves. Catheterization and Cardiovascular Interventions, 2021, 98, 176-183.	1.7	13
15	Methodological quality of COVID-19 clinical research. Nature Communications, 2021, 12, 943.	12.8	101
16	Impact of sex on outcomes after percutaneous repair of functional mitral valve regurgitation. Journal of Cardiac Surgery, 2021, 36, 1900-1903.	0.7	6
17	Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2021, 14, e009994.	3.9	17
18	Acute kidney injury after radial or femoral artery access in ST-segment elevation myocardial infarction: AKI-SAFARI. American Heart Journal, 2021, 234, 12-22.	2.7	10

#	ARTICLE	IF	CITATIONS
19	Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 450-457.	1.9	2
20	De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes. <i>CJC Open</i> , 2021, 3, 1091-1099.	1.5	1
21	Intraoperative Left Atrial Appendage Occluder Implantation with the Amplatzer Cardiac Plug. <i>Structural Heart</i> , 2021, 5, 420-421.	0.6	1
22	Targeted temperature management following out-of-hospital cardiac arrest: a systematic review and network meta-analysis of temperature targets. <i>Intensive Care Medicine</i> , 2021, 47, 1078-1088.	8.2	63
23	Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial. <i>Critical Care</i> , 2021, 25, 289.	5.8	15
24	Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2021, 385, 516-525.	27.0	129
25	The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 712-720.	1.0	21
26	Targeted temperature management after out-of-hospital cardiac arrest, no de-implementation required based on network meta analysis. Author's reply. <i>Intensive Care Medicine</i> , 2021, 47, 1507-1508.	8.2	6
27	Sweeping TTM conclusion may deprive many post-arrest patients of effective therapy. Author's reply. <i>Intensive Care Medicine</i> , 2021, 47, 1511-1512.	8.2	0
28	Methodological Rigor in Preclinical Cardiovascular Research: Contemporary Performance of AHA Scientific Publications. <i>Circulation Research</i> , 2021, 129, 887-889.	4.5	8
29	Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock. <i>Journal of the American Heart Association</i> , 2021, 10, e021570.	3.7	15
30	Modifiable Risk Factors and Residual Risk Following Coronary Revascularization. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 1138-1152.	2.4	5
31	A new electrocardiographic definition of left bundle branch block (LBBB) in patients after transcatheter aortic valve replacement (TAVR). <i>Journal of Electrocardiology</i> , 2020, 63, 167-172.	0.9	4
32	Journal Initiatives to Enhance Preclinical Research: Analyses of Stroke, <i>Nature Medicine</i> , Science Translational Medicine. <i>Stroke</i> , 2020, 51, 291-299.	2.0	14
33	Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 126.	6.1	87
34	Commentary: Geographic variation in the statin trials - underrepresentation of Asian populations. <i>International Journal of Cardiology</i> , 2020, 316, 47-48.	1.7	0
35	Long-term mortality and costs following use of Impella® for mechanical circulatory support: a population-based cohort study. <i>Canadian Journal of Anaesthesia</i> , 2020, 67, 1728-1737.	1.6	7
36	A Shifting Paradigm. <i>Chest</i> , 2020, 158, 2107-2118.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Contrast-free optical coherence tomography: Systematic evaluation of non-contrast media for intravascular assessment. PLoS ONE, 2020, 15, e0237588.	2.5	6
38	Evaluation of plasminogen activator inhibitor-1 as a biomarker of unplanned revascularization and major adverse cardiac events in coronary angiography and percutaneous coronary intervention. Thrombosis Research, 2020, 191, 125-133.	1.7	6
39	New-onset atrial fibrillation and associated outcomes and resource use among critically ill adults—a multicenter retrospective cohort study. Critical Care, 2020, 24, 15.	5.8	36
40	Percutaneous Atrialotomy for Left Atrial “to” Coronary Sinus Shunting in Asymptomatic Heart Failure. JACC: Cardiovascular Interventions, 2020, 13, 1236-1247.	2.9	33
41	Systematic review of pre-clinical therapies for post-operative atrial fibrillation. PLoS ONE, 2020, 15, e0241643.	2.5	4
42	Impact of trainee involvement on patient radiation exposure and contrast volumes during invasive cardiac procedures. Clinical and Investigative Medicine, 2020, 43, E18-E21.	0.6	0
43	Physician prediction of 1-year mortality in the cardiac catheterization laboratory. Coronary Artery Disease, 2020, Publish Ahead of Print, 403-410.	0.7	2
44	Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations. Journal of the American Heart Association, 2019, 8, e012228.	3.7	27
45	Percutaneous Mitral Repair as Salvage Therapy in Patients With Mitral Regurgitation and Refractory Cardiogenic Shock. Circulation: Cardiovascular Interventions, 2019, 12, e008435.	3.9	13
46	Female Authorship in Preclinical Cardiovascular Research. JACC Basic To Translational Science, 2019, 4, 471-477.	4.1	14
47	Spontaneous coronary artery dissection in cardiac sarcoidosis. Oxford Medical Case Reports, 2019, 2019, omz033.	0.4	6
48	Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations. Diabetes and Vascular Disease Research, 2019, 16, 478-482.	2.0	13
49	Systematic review of biological therapies for atrial fibrillation. Heart Rhythm, 2019, 16, 1399-1407.	0.7	4
50	Left Atrial Appendage Occlusion Guided by Intracardiac Echocardiography from the Right Ventricular Outflow Tract. Structural Heart, 2019, 3, 155-157.	0.6	1
51	Evaluation of a novel cardioversion intervention for atrial fibrillation: the Ottawa AF cardioversion protocol. Europace, 2019, 21, 708-715.	1.7	19
52	In-hospital outcomes of STEMI patients on warfarin undergoing primary PCI. Catheterization and Cardiovascular Interventions, 2019, 93, 41-47.	1.7	3
53	Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y ₁₂ receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 543-553.	1.0	15
54	Clinical performance of Rb-82 myocardial perfusion PET and Tc-99m-based SPECT in patients with extreme obesity. Journal of Nuclear Cardiology, 2019, 26, 275-283.	2.1	16

#	ARTICLE	IF	CITATIONS
55	Adenosine as a Marker and Mediator of Cardiovascular Homeostasis: A Translational Perspective. Cardiovascular & Hematological Disorders Drug Targets, 2019, 19, 109-131.	0.7	8
56	Role of plasminogen activator inhibitor-1 in coronary pathophysiology. Thrombosis Research, 2018, 164, 54-62.	1.7	39
57	Photoplethysmography using a smartphone application for assessment of ulnar artery patency: a randomized clinical trial. Cmaj, 2018, 190, E380-E388.	2.0	7
58	Evaluation of Cobalt and Chromium Levels Following Implantation of Cobalt Chromium Coronary Stents: A Pilot Study. Heart Lung and Circulation, 2018, 27, 763-766.	0.4	3
59	Transcatheter Aortic Valve Implantation (TAVI) for Native Aortic Valve Regurgitationâ€• A Systematic Review â€•. Circulation Journal, 2018, 82, 895-902.	1.6	14
60	Hyperglycaemia in comatose survivors of out-of-hospital cardiac arrest. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 442-449.	1.0	14
61	Incidence, predictors, and clinical outcomes of early stent thrombosis in acute myocardial infarction patients treated with primary percutaneous coronary angioplasty (insights from the U niversity of O Tj ETQq1 1 0.784314 rgBT /Overdo 842-848.	1.7	10
62	Letter by Ramirez and Hibbert Regarding Article, â€œConsideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies: A Statement From the <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> Councilâ€• Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e99-e100.	2.4	7
63	Percutaneous left atrial appendage closure for managing thromboembolic risk in atrial fibrillation. Cmaj, 2018, 190, E1227-E1230.	2.0	1
64	H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review. Cardiology, 2018, 140, 115-123.	1.4	17
65	Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thrombosis Journal, 2018, 16, 12.	2.1	83
66	A novel echocardiographic hemodynamic index for predicting outcome of aortic stenosis patients following transcatheter aortic valve replacement. PLoS ONE, 2018, 13, e0195641.	2.5	6
67	The Next Generation of Physician-Scientists: Adapting to Academic Cardiology in the 21st Century. Canadian Journal of Cardiology, 2018, 34, 1225-1228.	1.7	1
68	Optimal mean arterial pressure in comatose survivors of out-of-hospital cardiac arrest: An analysis of area below blood pressure thresholds. Resuscitation, 2018, 128, 175-180.	3.0	39
69	A Woman in Her 80s With Anterior ST-Elevation Myocardial Infarction andÂShock. Chest, 2017, 151, e5-e8.	0.8	1
70	Early Canadian Multicenter Experience With WATCHMAN for Percutaneous Left Atrial Appendage Closure. Journal of Cardiovascular Electrophysiology, 2017, 28, 396-401.	1.7	23
71	Sex Bias Is Increasingly Prevalent in Preclinical Cardiovascular Research: Implications for Translational Medicine and Health Equity for Women. Circulation, 2017, 135, 625-626.	1.6	54
72	Left Atrial Dissection After Percutaneous Transluminal Mitral Valvuloplasty. Canadian Journal of Cardiology, 2017, 33, 831.e5-831.e6.	1.7	1

#	ARTICLE	IF	CITATIONS
73	Impact of mean arterial pressure on clinical outcomes in comatose survivors of out-of-hospital cardiac arrest: Insights from the University of Ottawa Heart Institute Regional Cardiac Arrest Registry (CAPITAL-CARe). Resuscitation, 2017, 113, 27-32.	3.0	41
74	Association Between Self-Reported Potentially Modifiable Cardiac Risk Factors and Perceived Need to Improve Physical Health: A Population-Based Study. Journal of the American Heart Association, 2017, 6, .	3.7	16
75	Methodological Rigor in Preclinical Cardiovascular Studies. Circulation Research, 2017, 120, 1916-1926.	4.5	118
76	Remote solutions for telementoring point-of-care ultrasound echocardiography: The RESOLUTE study. Canadian Journal of Anaesthesia, 2017, 64, 1077-1078.	1.6	7
77	Progenitor Cells for Arterial Repair: Incremental Advancements towards Therapeutic Reality. Stem Cells International, 2017, 2017, 1-14.	2.5	26
78	A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheterization and Cardiovascular Interventions, 2016, 88, 107-115.	1.7	42
79	A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: A cautionary tale in managing patients with acute coronary syndromes. International Journal of Cardiology, 2016, 214, 423-425.	1.7	9
80	Impact of Center Experience on Patient Radiation Exposure During Transradial Coronary Angiography and Percutaneous Intervention: A Patient-Level, International, Collaborative, Multi-Center Analysis. Journal of the American Heart Association, 2016, 5, .	3.7	19
81	Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. Clinical Cardiology, 2016, 39, 19-23.	1.8	24
82	The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review. European Journal of Clinical Pharmacology, 2016, 72, 83-91.	1.9	6
83	Transcatheter Aortic Valve Implantation: Current and Evolving Indications. Canadian Journal of Cardiology, 2016, 32, 266-269.	1.7	11
84	Transfemoral vs Non-transfemoral Access for Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2015, 31, 1427-1438.	1.7	76
85	A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window. International Journal of Cardiology, 2015, 197, 318-325.	1.7	15
86	Clinical outcomes among patients with extreme obesity undergoing elective coronary revascularization: Evaluation of major complications in contemporary practice. International Journal of Cardiology, 2015, 186, 266-272.	1.7	5
87	Transcatheter aortic valve implantation in patients with bicuspid aortic valve: A patient level multi-center analysis. International Journal of Cardiology, 2015, 189, 282-288.	1.7	82
88	Natural History of Cardiac Arrest in Patients With Takotsubo Cardiomyopathy. American Journal of Cardiology, 2015, 115, 1466-1472.	1.6	24
89	Safety and Efficacy of Staged Percutaneous Coronary Intervention During Index Admission for ST-Elevation Myocardial Infarction With Multivessel Coronary Disease (Insights from the University of Ottawa Heart Institute) Tj ETQq1 1 0.78.4314 rgBT/Overload	1.6	16
90	A Comparative Pharmacodynamic Study of Ticagrelor versus Clopidogrel and Ticagrelor in Patients Undergoing Primary Percutaneous Coronary Intervention: The CAPITAL RELOAD Study. PLoS ONE, 2014, 9, e92078.	2.5	15

#	ARTICLE	IF	CITATIONS
91	Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trial. Cmaj, 2014, 186, E427-E434.	2.0	11
92	Circulating Endothelial Progenitor Cells and In-Stent Restenosis: Friend, Foe, or None of the Above?. Canadian Journal of Cardiology, 2014, 30, 6-7.	1.7	1
93	Left Atrial Myxoma: A Rare Cause of Dyspnea. Canadian Journal of Cardiology, 2014, 30, 465.e1-465.e2.	1.7	3
94	The Evolution of Coronary Stents: A Brief Review. Canadian Journal of Cardiology, 2014, 30, 35-45.	1.7	125
95	Superiority of Ticagrelor Over Clopidogrel in Patients After Cardiac Arrest Undergoing Therapeutic Hypothermia. Canadian Journal of Cardiology, 2014, 30, 1396-1399.	1.7	21
96	Glycogen Synthase Kinase-3 β Inhibition Augments Diabetic Endothelial Progenitor Cell Abundance and Functionality via Cathepsin B: A Novel Therapeutic Opportunity for Arterial Repair. Diabetes, 2014, 63, 1410-1421.	0.6	11
97	Endovascular cooling catheter related thrombosis in patients undergoing therapeutic hypothermia for out of hospital cardiac arrest. Resuscitation, 2014, 85, 1354-1358.	3.0	38
98	Performance of transcatheter aortic valve implantation in patients with bicuspid aortic valve: Systematic review. International Journal of Cardiology, 2014, 176, 562-564.	1.7	23
99	Heat shock protein 27 attenuates neointima formation and accelerates reendothelialization after arterial injury and stent implantation: importance of vascular endothelial growth factor up-regulation. FASEB Journal, 2014, 28, 594-602.	0.5	24
100	Perivalvular Approach to Percutaneous Coronary Intervention After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 2014, 30, 1109.e1-1109.e2.	1.7	3
101	The Effect of Statins on Circulating Endothelial Progenitor Cells in Humans. Journal of Cardiovascular Pharmacology, 2013, 62, 491-496.	1.9	35
102	Bivalirudin for Primary Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2012, 5, 805-812.	3.9	31
103	Infective Endocarditis Presenting as ST-Elevation Myocardial Infarction: An Angiographic Diagnosis. Canadian Journal of Cardiology, 2012, 28, 515.e15-515.e17.	1.7	12
104	Transradial Versus Transfemoral Artery Approach for Coronary Angiography and Percutaneous Coronary Intervention in the Extremely Obese. JACC: Cardiovascular Interventions, 2012, 5, 819-826.	2.9	74
105	Pathogenesis of Neointima Formation Following Vascular Injury. Cardiovascular & Hematological Disorders Drug Targets, 2011, 11, 30-39.	0.7	67
106	Coronary stent fracture. Cmaj, 2011, 183, E756-E756.	2.0	6
107	Pre-Procedural Atorvastatin Mobilizes Endothelial Progenitor Cells: Clues to the Salutary Effects of Statins on Healing of Stented Human Arteries. PLoS ONE, 2011, 6, e16413.	2.5	33
108	Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3 β inhibitor. Cardiovascular Research, 2010, 86, 338-345.	3.8	48

#	ARTICLE	IF	CITATIONS
109	Ventricular tachycardia following tube thoracotomy. <i>Europace</i> , 2010, 12, 1504-1506.	1.7	5
110	Pulmonary hypertension. <i>Canadian Journal of Cardiology</i> , 2010, 26, e176.	1.7	2
111	Cardiovascular complications of <i>Salmonella enteritidis</i> infection. <i>Canadian Journal of Cardiology</i> , 2010, 26, e323-e325.	1.7	23
112	Inhibition of endothelial progenitor cell glycogen synthase kinase-3 β results in attenuated neointima formation and enhanced re-endothelialization after arterial injury. <i>Cardiovascular Research</i> , 2009, 83, 16-23.	3.8	41
113	c-kit-Immunopositive vascular progenitor cells populate human coronary in-stent restenosis but not primary atherosclerotic lesions. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H518-H524.	3.2	51
114	Involvement of Progenitor Cells in Vascular Repair. <i>Trends in Cardiovascular Medicine</i> , 2003, 13, 322-326.	4.9	47